Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial

Transplant Proc. 1996 Dec;28(6):3221-2.

Authors

T van Gelder¹, R Zietse, J N Yzermans, J Rischen-Vos, L M Vaessen, W Weimar

Affiliation

¹ Department of Internal Medicine, University Hospital Rotterdam, The Netherlands.

PMID: 8962247

No abstract available

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antilymphocyte Serum
Cyclosporine / therapeutic use
Double-Blind Method
Follow-Up Studies
Graft Rejection / prevention & control*
Graft Survival / immunology*
Humans
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology*
Kidney Transplantation / mortality
Methylprednisolone / therapeutic use
Placebos
Prednisone / therapeutic use
Receptors, Interleukin-2 / immunology*
Survival Rate
Time Factors
Transplantation, Homologous

Substances

Antibodies, Monoclonal
Antilymphocyte Serum
Immunosuppressive Agents
Placebos
Receptors, Interleukin-2
Cyclosporine
inolimomab
Prednisone
Methylprednisolone